Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients

Hye Won Kim, Gang Jee Ko, Young Sun Kang, Mi Hwa Lee, Hye Kyoung Song, Hyoung Kyu Kim, Dae-Ryong Cha

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Aim: Vascular endothelial growth factor (VEGF) is important in the pathogenesis of diabetic microvascular complications and the genetic polymorphism of this gene may contribute to the development and progression of diabetic microvascular complications. In this study, we investigated whether a genetic polymorphism of VEGF is associated with diabetic complications. Methods: A total of 398 type 2 diabetic patients and 526 healthy controls were enrolled. The study subjects were divided based on the state of nephropathy, retinopathy and neuropathy. The VEGF 936 C/T polymorphism was evaluated using standard PCR techniques, and plasma and urinary levels of VEGF were determined by enzyme-linked immunosorbent assay. Results: There was no difference in VEGF genotype distribution between the control and diabetic patients based on the state of diabetic nephropathy and neuropathy. However, a higher frequency of the TT genotype was observed in patients with proliferative diabetic retinopathy. Additionally, plasma levels of VEGF were significantly higher in the TT genotype. However, urinary levels of VEGF did not show a significant relationship with the VEGF genotype. Urinary VEGF levels showed a significant relationship with urinary albumin excretion, proteinuria, serum creatinine level and creatinine clearance, as well as fasting blood glucose levels, postprandial 2 h glucose levels and C-reactive protein. Conclusion: Our study suggests that the 936 C/T polymorphism of the VEGF gene may be an important factor determining plasma VEGF levels and that its polymorphism is related with diabetic retinopathy. Urinary levels of VEGF are not associated with plasma VEGF levels and associated with the stage of diabetic nephropathy.

Original languageEnglish
Pages (from-to)681-688
Number of pages8
JournalNephrology
Volume14
Issue number7
DOIs
Publication statusPublished - 2009 Oct 1

Fingerprint

Vascular Endothelial Growth Factor C
Diabetes Complications
Vascular Endothelial Growth Factor A
Genotype
Diabetic Nephropathies
Diabetic Retinopathy
Genetic Polymorphisms
Creatinine
Diabetic Neuropathies
Proteinuria
C-Reactive Protein
Genes
Blood Glucose
Albumins
Fasting

Keywords

  • Diabetic complication
  • Polymorphism
  • Type 2 diabetic patient
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Nephrology

Cite this

Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients. / Kim, Hye Won; Ko, Gang Jee; Kang, Young Sun; Lee, Mi Hwa; Song, Hye Kyoung; Kim, Hyoung Kyu; Cha, Dae-Ryong.

In: Nephrology, Vol. 14, No. 7, 01.10.2009, p. 681-688.

Research output: Contribution to journalArticle

Kim, Hye Won ; Ko, Gang Jee ; Kang, Young Sun ; Lee, Mi Hwa ; Song, Hye Kyoung ; Kim, Hyoung Kyu ; Cha, Dae-Ryong. / Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients. In: Nephrology. 2009 ; Vol. 14, No. 7. pp. 681-688.
@article{fa620ede6d2a48d28379d2f4d12413e4,
title = "Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients",
abstract = "Aim: Vascular endothelial growth factor (VEGF) is important in the pathogenesis of diabetic microvascular complications and the genetic polymorphism of this gene may contribute to the development and progression of diabetic microvascular complications. In this study, we investigated whether a genetic polymorphism of VEGF is associated with diabetic complications. Methods: A total of 398 type 2 diabetic patients and 526 healthy controls were enrolled. The study subjects were divided based on the state of nephropathy, retinopathy and neuropathy. The VEGF 936 C/T polymorphism was evaluated using standard PCR techniques, and plasma and urinary levels of VEGF were determined by enzyme-linked immunosorbent assay. Results: There was no difference in VEGF genotype distribution between the control and diabetic patients based on the state of diabetic nephropathy and neuropathy. However, a higher frequency of the TT genotype was observed in patients with proliferative diabetic retinopathy. Additionally, plasma levels of VEGF were significantly higher in the TT genotype. However, urinary levels of VEGF did not show a significant relationship with the VEGF genotype. Urinary VEGF levels showed a significant relationship with urinary albumin excretion, proteinuria, serum creatinine level and creatinine clearance, as well as fasting blood glucose levels, postprandial 2 h glucose levels and C-reactive protein. Conclusion: Our study suggests that the 936 C/T polymorphism of the VEGF gene may be an important factor determining plasma VEGF levels and that its polymorphism is related with diabetic retinopathy. Urinary levels of VEGF are not associated with plasma VEGF levels and associated with the stage of diabetic nephropathy.",
keywords = "Diabetic complication, Polymorphism, Type 2 diabetic patient, Vascular endothelial growth factor",
author = "Kim, {Hye Won} and Ko, {Gang Jee} and Kang, {Young Sun} and Lee, {Mi Hwa} and Song, {Hye Kyoung} and Kim, {Hyoung Kyu} and Dae-Ryong Cha",
year = "2009",
month = "10",
day = "1",
doi = "10.1111/j.1440-1797.2009.01085.x",
language = "English",
volume = "14",
pages = "681--688",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients

AU - Kim, Hye Won

AU - Ko, Gang Jee

AU - Kang, Young Sun

AU - Lee, Mi Hwa

AU - Song, Hye Kyoung

AU - Kim, Hyoung Kyu

AU - Cha, Dae-Ryong

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Aim: Vascular endothelial growth factor (VEGF) is important in the pathogenesis of diabetic microvascular complications and the genetic polymorphism of this gene may contribute to the development and progression of diabetic microvascular complications. In this study, we investigated whether a genetic polymorphism of VEGF is associated with diabetic complications. Methods: A total of 398 type 2 diabetic patients and 526 healthy controls were enrolled. The study subjects were divided based on the state of nephropathy, retinopathy and neuropathy. The VEGF 936 C/T polymorphism was evaluated using standard PCR techniques, and plasma and urinary levels of VEGF were determined by enzyme-linked immunosorbent assay. Results: There was no difference in VEGF genotype distribution between the control and diabetic patients based on the state of diabetic nephropathy and neuropathy. However, a higher frequency of the TT genotype was observed in patients with proliferative diabetic retinopathy. Additionally, plasma levels of VEGF were significantly higher in the TT genotype. However, urinary levels of VEGF did not show a significant relationship with the VEGF genotype. Urinary VEGF levels showed a significant relationship with urinary albumin excretion, proteinuria, serum creatinine level and creatinine clearance, as well as fasting blood glucose levels, postprandial 2 h glucose levels and C-reactive protein. Conclusion: Our study suggests that the 936 C/T polymorphism of the VEGF gene may be an important factor determining plasma VEGF levels and that its polymorphism is related with diabetic retinopathy. Urinary levels of VEGF are not associated with plasma VEGF levels and associated with the stage of diabetic nephropathy.

AB - Aim: Vascular endothelial growth factor (VEGF) is important in the pathogenesis of diabetic microvascular complications and the genetic polymorphism of this gene may contribute to the development and progression of diabetic microvascular complications. In this study, we investigated whether a genetic polymorphism of VEGF is associated with diabetic complications. Methods: A total of 398 type 2 diabetic patients and 526 healthy controls were enrolled. The study subjects were divided based on the state of nephropathy, retinopathy and neuropathy. The VEGF 936 C/T polymorphism was evaluated using standard PCR techniques, and plasma and urinary levels of VEGF were determined by enzyme-linked immunosorbent assay. Results: There was no difference in VEGF genotype distribution between the control and diabetic patients based on the state of diabetic nephropathy and neuropathy. However, a higher frequency of the TT genotype was observed in patients with proliferative diabetic retinopathy. Additionally, plasma levels of VEGF were significantly higher in the TT genotype. However, urinary levels of VEGF did not show a significant relationship with the VEGF genotype. Urinary VEGF levels showed a significant relationship with urinary albumin excretion, proteinuria, serum creatinine level and creatinine clearance, as well as fasting blood glucose levels, postprandial 2 h glucose levels and C-reactive protein. Conclusion: Our study suggests that the 936 C/T polymorphism of the VEGF gene may be an important factor determining plasma VEGF levels and that its polymorphism is related with diabetic retinopathy. Urinary levels of VEGF are not associated with plasma VEGF levels and associated with the stage of diabetic nephropathy.

KW - Diabetic complication

KW - Polymorphism

KW - Type 2 diabetic patient

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=70349751398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349751398&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1797.2009.01085.x

DO - 10.1111/j.1440-1797.2009.01085.x

M3 - Article

C2 - 19796028

AN - SCOPUS:70349751398

VL - 14

SP - 681

EP - 688

JO - Nephrology

JF - Nephrology

SN - 1320-5358

IS - 7

ER -